Biotech United Therapeutics (UTHR) beat Wall Street's earnings target early Tue. in part on strong sales of its inhalable pulmonary arterial hypertension drug Adcirca. Still, market research firm ISI Group said in a client note that "$4 million of this (revenue) was due to an accelerated shipment of inventory to wholesalers in December to avoid any shortages around the holidays." Revenue rose 25% to $243.8 mil, about $10 mil over consensus. EPS more than doubled to $1.60 vs. analyst views for $1.25. Shares rose 0.9% to 58.20.